Holen Sie sich die Stockscreener-App
0.7523
5.55%
-0.0442
Schlusskurs vom Vortag:
$0.7965
Offen:
$0.7726
24-Stunden-Volumen:
47,535
Relative Volume:
0.44
Marktkapitalisierung:
$21.78M
Einnahmen:
$26.55M
Nettoeinkommen (Verlust:
$-91.72M
KGV:
-0.2099
EPS:
-3.584
Netto-Cashflow:
$-13.25M
1W Leistung:
+3.51%
1M Leistung:
-5.77%
6M Leistung:
-39.82%
1J Leistung:
-57.97%
1-Tages-Spanne:
$0.7517
$0.775
1-Wochen-Bereich:
$0.70
$0.9586
52-Wochen-Spanne:
$0.667
$4.35
Celularity Inc Stock (CELU) Company Profile
Firmenname
Celularity Inc
Sektor
Branche
Telefon
(908) 768-2170
Adresse
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
0.7523 | 21.78M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-30 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-06 | Herabstufung | Truist | Buy → Hold |
| 2022-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Celularity Inc Aktie (CELU) Neueste Nachrichten
Celularity Inc (CELU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celularity Inc (CELU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celularity Inc (CELU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celularity Inc (CELU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celularity Inc (CELUW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Celularity Inc (CELUW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celularity Inc (CELUW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celularity Inc (CELUW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celularity Inc (CELUW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celularity Inc (CELUW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celularity Inc (CELUW) Institutional Confidence - TradingKey
Celularity Inc (CELUW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celularity Inc (CELU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celularity Inc (CELU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celularity Inc (CELU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Celularity Inc (CELU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celularity Inc (CELU) Institutional Confidence - TradingKey
Celularity Inc (CELUW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celularity Inc. Warrant (CELUW) Holds at $0.01 Amid Minimal Volatility – Key Levels in FocusPCR Moving Average - newsline.com
Celularity Inc. 8-K Filing June 2026: Nasdaq Listing, Company Details, and Securities Information - Minichart
Celularity Faces Nasdaq Listing Compliance Risk After Notice - TipRanks
Celularity receives Nasdaq notice for non-compliance with $35 million market value rule - Investing.com
Celularity Received Notice of Noncompliance - TradingView
[8-K] Celularity Inc Reports Material Event - Stock Titan
Celularity (CELU) Slips 6% as Stock Approaches Key Support at $0.69Price Gap Fill - newsline.com
Celularity Inc. (CELU) Slips 7.4% as Selling Pressure Continues Near Key SupportLow Volatility Picks - newsline.com
CELU - Finviz
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - The Manila Times
New Florida law lets doctors use placental cell therapy before FDA approval - Stock Titan
Celularity names Rick Gonzalez as chief commercial officer - Investing.com UK
Celularity: Actions Are Intended to Streamline Business and Concentrate Resources >CELU - Moomoo
Celularity refocuses on cell therapy after biomaterials sale - Investing.com
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - TipRanks
Celularity names Rick Gonzalez as Chief Commercial Officer - TradingView
New Celularity (NASDAQ: CELU) CCO to drive cenplacel-L and Lifebank growth - Stock Titan
Celularity refocuses on cell therapy after biomaterials sale By Investing.com - Investing.com UK
Celularity Releases CEO Letter to Shareholders - The Manila Times
Celularity outlines placenta cell therapy push to extend health span - Stock Titan
Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer - geneonline.com
Celularity names Rick Gonzalez as chief commercial officer By Investing.com - Investing.com Australia
Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer, Effective May 29, 2026 - marketscreener.com
Celularity Receives Nasdaq Notice Regarding Form 10-Q - marketscreener.com
Celularity face Nasdaq listing rule breach after missing Q1 10-Q SEC filing - MSN
Celularity gets Nasdaq notice for delayed Q1 2026 Form 10-Q filing, must submit compliance plan by July 28. - Pluang
Celularity Inc. Notified of Non-Compliance with Nasdaq Listing Rule Due to Delayed 10-Q Filing - Quiver Quantitative
Nasdaq flags Celularity for missing Q1 2026 10-Q filing - Stock Titan
Celularity Enters Settlement, Restructuring Financing Obligations - TipRanks
Celularityenters settlement agreement with Helena on May 21, 2026 - marketscreener.com
Celularity Settles With Helena; $500,000 Upfront, 5x$100,000 Payments and $2.5M Note Rights - TradingView
Celularity (NASDAQ: CELU) restructures Helena preferred stock deal with cash and note rights - Stock Titan
Celularity Inc. (CELU) Surges 8% to $0.99 as Stock Tests Key ResistanceEarly Entry Signals - The Legal Advocate
Finanzdaten der Celularity Inc-Aktie (CELU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):